BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GlaxoSmithKline readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies GlaxoSmithKline's drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06567782-2162@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06567782)
DESCRIPTION:Dostarlimab\, phase 2.\nStudy: A Study of Neoadjuvant Dostarlim
 ab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously U
 ntreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellit
 e Stable (MSS) Colon Cancer\nEstimated primary completion: 23 November 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06567782
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03981796-2052@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:Niraparib: Phase 3 readout est. (NCT03981796)
DESCRIPTION:Niraparib\, phase 3\, Endometrial Cancer.\nStudy: A Study to Ev
 aluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carbopl
 atin-paclitaxel in Participants With Recurrent or Primary Advanced Endomet
 rial Cancer\nEstimated primary completion: 26 November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03981796
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317311-2162@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06317311)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: A Study of 
 Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Partici
 pants With Primary Advanced or Recurrent Endometrial Cancer\nEstimated pri
 mary completion: 14 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06317311
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04641247-2052@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Niraparib: Phase 2 readout est. (NCT04641247)
DESCRIPTION:Niraparib\, phase 2.\nStudy: A Long-term Treatment Extension St
 udy of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TES
 ARO-sponsored Niraparib Study\nEstimated primary completion: 28 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04641247
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05757102-4142@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270127
SUMMARY:Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol): Phas
 e 3 readout est. (NCT05757102)
DESCRIPTION:Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)\,
  phase 3\, Asthma.\nStudy: A Study to Compare the Efficacy\, Safety and To
 lerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma\nEstima
 ted primary completion: 26 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/fluticasone-furoate-umeclidinium-vilanterol#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05757102
URL:https://assetmemo.bio/drug/fluticasone-furoate-umeclidinium-vilanterol#
 upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671001-1527@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Depemokimab: Phase 3 readout est. (NCT07671001)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: A Study of Depemokimab 
 in Participants of 6 to 11 Years of Age\nEstimated primary completion: 1 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/depemokima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 671001
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07519395-1312@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:BLU-5937: Phase 2 readout est. (NCT07519395)
DESCRIPTION:BLU-5937\, phase 2\, Irritable Bowel Syndrome.\nStudy: A Study 
 to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo i
 n Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bo
 wel Syndrome - Mixed (IBS-M)\nEstimated primary completion: 9 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/blu-5937#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07519395
URL:https://assetmemo.bio/drug/blu-5937#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07201051-1528@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:GSK3862995: Phase 2 readout est. (NCT07201051)
DESCRIPTION:GSK3862995\, phase 2.\nStudy: A Study to Assess the Effectivene
 ss and Safety of GSK3862995B in Adults With Bronchiectasis\nEstimated prim
 ary completion: 4 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/gsk3862995#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07201051
URL:https://assetmemo.bio/drug/gsk3862995#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06537414-10996@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Daplusiran/Tomligisiran: Phase 2 readout est. (NCT06537414)
DESCRIPTION:Daplusiran/Tomligisiran\, phase 2\, Chronic Hepatitis B.\nStudy
 : A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Fol
 lowed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB
 )\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/daplusiran-tomligisiran#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06537414
URL:https://assetmemo.bio/drug/daplusiran-tomligisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796907-2162@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Dostarlimab: Phase 1/2 readout est. (NCT06796907)
DESCRIPTION:Dostarlimab\, phase 1/2.\nStudy: A Study of Mocertatug Rezeteca
 n in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEH
 OLD-2)\nEstimated primary completion: 21 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06796907
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06847867-3097@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Momelotinib: Phase 2 readout est. (NCT06847867)
DESCRIPTION:Momelotinib\, phase 2\, Myelodysplastic Syndromes.\nStudy: A St
 udy of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome\
 nEstimated primary completion: 14 July 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/momelotinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06847867
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650084-1312@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:BLU-5937: Phase 3 readout est. (NCT07650084)
DESCRIPTION:BLU-5937\, phase 3.\nStudy: A 24-Week Study of the Efficacy and
  Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extens
 ion\nEstimated primary completion: 27 August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/blu-5937#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07650084
URL:https://assetmemo.bio/drug/blu-5937#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545681-11207@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:GSK3772701: Phase 2 readout est. (NCT07545681)
DESCRIPTION:GSK3772701\, phase 2\, Malaria.\nStudy: A Phase 2A Study of a N
 ovel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. 
 Falciparum Malaria\nEstimated primary completion: 8 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/gsk3772701#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07545681
URL:https://assetmemo.bio/drug/gsk3772701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640049-2162@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20271024
DTEND;VALUE=DATE:20271025
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06640049)
DESCRIPTION:Dostarlimab\, phase 2\, Rectal Cancer.\nStudy: A Study of Dosta
 rlimab in Participants With Untreated Locally Advanced Rectal Cancer in Ch
 ina\nEstimated primary completion: 24 October 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06640049
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05334368-1527@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20271029
DTEND;VALUE=DATE:20271030
SUMMARY:Depemokimab: Phase 3 readout est. (NCT05334368)
DESCRIPTION:Depemokimab\, phase 3.\nStudy: Depemokimab in Participants With
  Hypereosinophilic Syndrome\, Efficacy\, and Safety Trial\nEstimated prima
 ry completion: 29 October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/depemokimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05334368
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602777-2501@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Risvutatug rezetecan: Phase 1/2 readout est. (NCT07602777)
DESCRIPTION:Risvutatug rezetecan\, phase 1/2.\nStudy: A Study Evaluating th
 e Efficacy and Safety of Risvutatug Rezetecan in Participants With Advance
 d Sarcomas (EMBOLD Sarcoma-202)\nEstimated primary completion: 5 November 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-reze
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07602777
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099898-2501@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07099898)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Canc
 er (SCLC) [EMBOLD SCLC-301]\nEstimated primary completion: 5 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 099898
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06613698-6673@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Gatuzosiran: Phase 2 readout est. (NCT06613698)
DESCRIPTION:Gatuzosiran\, phase 2.\nStudy: A Study to Investigate the Safet
 y and Efficacy of GSK4532990 Compared With Placebo in Adult Participants A
 ged 18 to 70 Years With Alcohol-related Liver Disease\nEstimated primary c
 ompletion: 26 November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/gatuzosiran#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06613698
URL:https://assetmemo.bio/drug/gatuzosiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689201-11196@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20271129
DTEND;VALUE=DATE:20271130
SUMMARY:Velzatinib: Phase 2 readout est. (NCT07689201)
DESCRIPTION:Velzatinib\, phase 2.\nStudy: A Study of Velzatinib in Particip
 ants With Metastatic and/or Unresectable GIST After Imatinib\, Sunitinib\,
  Regorafenib\, and Pimitespib\nEstimated primary completion: 29 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/velzatinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07689201
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526624-2501@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT06526624)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell L
 ung Cancer\nEstimated primary completion: 30 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06526624
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05384626-10952@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:neladalkib: Phase 1/2 readout est. (NCT05384626)
DESCRIPTION:neladalkib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other So
 lid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-
 1)\nEstimated primary completion: December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/neladalkib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05384626
URL:https://assetmemo.bio/drug/neladalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05118789-2824@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zidesamtinib: Phase 1/2 readout est. (NCT05118789)
DESCRIPTION:Zidesamtinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Othe
 r Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/zidesamtinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05118789
URL:https://assetmemo.bio/drug/zidesamtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098403-3551@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07098403)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Trial of SHR-1905 i
 n Subjects With Severe Uncontrolled Asthma\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felcore
 kibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07098403
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979323-1527@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280105
DTEND;VALUE=DATE:20280106
SUMMARY:Depemokimab: Phase 3 readout est. (NCT06979323)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: Depemokimab Asthma Imag
 ing and Bronchoscopy Sub-Study\nEstimated primary completion: 5 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/depemokimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06979323
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286331-9165@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07286331)
DESCRIPTION:GSK 5733584\, phase 3.\nStudy: A Study to Investigate Mocertatu
 g Rezetecan Compared With Chemotherapy in Participants With Endometrial Ca
 ncer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometri
 al01)\nEstimated primary completion: 29 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/gsk-5733584#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07286331
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07143448-234@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:HS235: Phase 1/2 readout est. (NCT07143448)
DESCRIPTION:HS235\, phase 1/2\, Pulmonary Arterial Hypertension.\nStudy: A 
 Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in A
 dults\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/hs235#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07143448
URL:https://assetmemo.bio/drug/hs235#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07332455-11197@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:GSK5471713: Phase 1/2 readout est. (NCT07332455)
DESCRIPTION:GSK5471713\, phase 1/2.\nStudy: First-Time-in-Human Study of GS
 K5471713 in Adults With mCRPC\nEstimated primary completion: 24 March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/gsk5471713#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07332455
URL:https://assetmemo.bio/drug/gsk5471713#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221188-6690@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07221188)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Clinical S
 tudy to Investigate the Safety and Tolerability of Efimosfermin Alfa Injec
 tion in Participants With Known or Suspected F2- or F3-stage MASH\nEstimat
 ed primary completion: 24 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/efimosfermin-alfa#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07221188
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221227-6690@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280329
DTEND;VALUE=DATE:20280330
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07221227)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Pivotal Cl
 inical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-
 confirmed F2- or F3-stage MASH\nEstimated primary completion: 29 March 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/efimosfermin-alfa#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0722
 1227
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824882-2501@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Risvutatug rezetecan: Phase 2 readout est. (NCT07824882)
DESCRIPTION:Risvutatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase II Study of HS-20093 Injection Combined With Adebrelimab Ver
 sus HS-20093 Injection in Previously Treated Patients With Advanced or Met
 astatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic
  Alterations\nEstimated primary completion: 30 March 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07824882
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132827-3551@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07132827)
DESCRIPTION:Felcorekibart\, phase 3.\nStudy: Efficacy and Safety of SHR-190
 5 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps\nEst
 imated primary completion: April 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/felcorekibart#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07132827
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218926-11196@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Velzatinib: Phase 3 readout est. (NCT07218926)
DESCRIPTION:Velzatinib\, phase 3\, Gastrointestinal Stromal Tumor.\nStudy: 
 A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With
  Gastrointestinal Stromal Tumors After Imatinib Therapy\nEstimated primary
  completion: 30 May 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/velzatinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07218926
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06256588-2162@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT06256588)
DESCRIPTION:Dostarlimab\, phase 3.\nStudy: A Study of Dostarlimab vs Placeb
 o After Chemoradiation in Adult Participants With Locally Advanced Unresec
 ted Head and Neck Squamous Cell Carcinoma\nEstimated primary completion: 3
 0 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dostarli
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06256588
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06920043-6690@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280703
DTEND;VALUE=DATE:20280704
SUMMARY:Efimosfermin alfa: Phase 2 readout est. (NCT06920043)
DESCRIPTION:Efimosfermin alfa\, phase 2\, MASH / NASH.\nStudy: A Study of E
 fimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensa
 ted) Due to MASH\nEstimated primary completion: 3 July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06920043
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714839-3152@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280803
DTEND;VALUE=DATE:20280804
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT05714839)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: A 
 Study to Investigate the Safety and Efficacy of Belantamab for the Treatme
 nt of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
 nts\nEstimated primary completion: 3 August 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05714839
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791043-6690@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280811
DTEND;VALUE=DATE:20280812
SUMMARY:Efimosfermin alfa: Phase 2 readout est. (NCT07791043)
DESCRIPTION:Efimosfermin alfa\, phase 2.\nStudy: A Study to Investigate the
  Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult P
 articipants With Alcohol-related Liver Disease (ALD)\nEstimated primary co
 mpletion: 11 August 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/efimosfermin-alfa#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07791043
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213609-11216@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280928
DTEND;VALUE=DATE:20280929
SUMMARY:GSK5460025: Phase 1/2 readout est. (NCT07213609)
DESCRIPTION:GSK5460025\, phase 1/2.\nStudy: A Study to Investigate the Safe
 ty and Preliminary Efficacy of GSK5460025 Alone or in Combination With Oth
 er Anti-cancer Agents in Participants With Solid Tumors\nEstimated primary
  completion: 28 September 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/gsk5460025#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07213609
URL:https://assetmemo.bio/drug/gsk5460025#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959095-1527@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20281213
DTEND;VALUE=DATE:20281214
SUMMARY:Depemokimab: Phase 3 readout est. (NCT06959095)
DESCRIPTION:Depemokimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: Depemokimab as an Extended Treatment Duration Biologic in Adults W
 ith Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation\n
 Estimated primary completion: 13 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/depemokimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06959095
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961214-1527@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20281213
DTEND;VALUE=DATE:20281214
SUMMARY:Depemokimab: Phase 3 readout est. (NCT06961214)
DESCRIPTION:Depemokimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: Depemokimab as an Extended Treatment Duration Biologic in Adults W
 ith Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (
 ENDURA-2)\nEstimated primary completion: 13 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/depemokimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06961214
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464327-2501@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07464327)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase III Study of HS-20093 Injection Combined With Adebrelimab Ve
 rsus Docetaxel in Previously Treated Patients With Advanced or Metastatic 
 Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterat
 ions\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07464327
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123779-234@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:HS235: Phase 1/2 readout est. (NCT07123779)
DESCRIPTION:HS235\, phase 1/2\, Heart Failure.\nStudy: HS235 Study in Overw
 eight and Obese Participants With Combined Pre and Post-Capillary Pulmonar
 y Hypertension Due to Heart Failure With Preserved Ejection Fraction\nEsti
 mated primary completion: January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/hs235#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07123779
URL:https://assetmemo.bio/drug/hs235#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06885034-2501@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290109
DTEND;VALUE=DATE:20290110
SUMMARY:Risvutatug rezetecan: Phase 1/2 readout est. (NCT06885034)
DESCRIPTION:Risvutatug rezetecan\, phase 1/2.\nStudy: A Study to Test the S
 afety and Effectiveness of GSK5764227\, Alone or With Other Treatments\, i
 n Participants With Advanced Gastrointestinal Cancers That Cannot be Surgi
 cally Removed (EMBOLD PanGI-201)\nEstimated primary completion: 9 January 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-reze
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06885034
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780643-3551@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780643)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Study to Investigat
 e the Efficacy and Safety of GSK5784283 Compared With Placebo in Participa
 nts With Uncontrolled Asthma (PERSIST ASTHMA-1)\nEstimated primary complet
 ion: 15 February 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/felcorekibart#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07780643
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614360-3152@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07614360)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Stud
 y of Alternative and Approved Dosing Regimens of Belantamab Mafodotin\, Bo
 rtezomib\, and Dexamethasone (BVd) in Participants With Relapsed/Refractor
 y Multiple Myeloma\nEstimated primary completion: 28 February 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07614360
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782957-3551@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07782957)
DESCRIPTION:Felcorekibart\, phase 3.\nStudy: A Study to Assess the Efficacy
  and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Partici
 pants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)\nEstimated pr
 imary completion: 6 March 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/felcorekibart#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07782957
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782970-3551@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07782970)
DESCRIPTION:Felcorekibart\, phase 3.\nStudy: A Study to Assess the Efficacy
  and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhi
 nosinusitis With Nasal Polyps (CRSwNP)\nEstimated primary completion: 6 Ma
 rch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felcorekiba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7782970
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915791-3551@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290307
DTEND;VALUE=DATE:20290308
SUMMARY:Felcorekibart: Phase 2 readout est. (NCT07915791)
DESCRIPTION:Felcorekibart\, phase 2\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Assess the Efficacy and Safety of Co-administration o
 f GSK3862995B With GSK5784283 in Adult Participants With Moderate to Sever
 e Chronic Obstructive Pulmonary Disease (COPD)\nEstimated primary completi
 on: 7 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fel
 corekibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07915791
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05855200-2162@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290319
DTEND;VALUE=DATE:20290320
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT05855200)
DESCRIPTION:Dostarlimab\, phase 3.\nStudy: Study of Perioperative Dostarlim
 ab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable 
 Colon Cancer\nEstimated primary completion: 19 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05855200
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177339-1527@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290402
DTEND;VALUE=DATE:20290403
SUMMARY:Depemokimab: Phase 3 readout est. (NCT07177339)
DESCRIPTION:Depemokimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: eValuating the Efficacy and Safety of InitiatinG depemokImab earLy
  therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Infl
 ammation\nEstimated primary completion: 2 April 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/depemokimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07177339
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782996-3551@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290504
DTEND;VALUE=DATE:20290505
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07782996)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Study to Investigat
 e the Efficacy and Safety of GSK5784283 Compared With Placebo in Participa
 nts With Uncontrolled Asthma (PERSIST ASTHMA-2)\nEstimated primary complet
 ion: 4 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felc
 orekibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07782996
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602855-2501@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:Risvutatug rezetecan: Phase 1/2 readout est. (NCT07602855)
DESCRIPTION:Risvutatug rezetecan\, phase 1/2.\nStudy: A Study of Risvutatug
  Rezetecan in Combination With Ivonescimab in Participants With Advanced S
 olid Tumors (EMBOLD PanTumour-103)\nEstimated primary completion: 22 June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-reze
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07602855
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780656-3551@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290720
DTEND;VALUE=DATE:20290721
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780656)
DESCRIPTION:Felcorekibart\, phase 3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Investigate the Efficacy and Safety of GSK5784283 (Fe
 lcorekibart) Compared With Placebo in Participants With Moderate to Very S
 evere COPD (PERSIST COPD-2)\nEstimated primary completion: 20 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/felcorekibart#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07780656
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780669-3551@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290720
DTEND;VALUE=DATE:20290721
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780669)
DESCRIPTION:Felcorekibart\, phase 3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Investigate the Efficacy and Safety of GSK5784283 (Fe
 lcorekibart) Compared With Placebo in Participants With Moderate to Very S
 evere COPD (PERSIST COPD-1)\nEstimated primary completion: 20 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/felcorekibart#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07780669
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684599-2162@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290723
DTEND;VALUE=DATE:20290724
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT07684599)
DESCRIPTION:Dostarlimab\, phase 3\, Endometrial Cancer.\nStudy: A Study to 
 Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants
  With MMRp Endometrial Cancer (BEHOLD-Endometrial02)\nEstimated primary co
 mpletion: 23 July 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dostarlimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07684599
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07694427-9165@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290906
DTEND;VALUE=DATE:20290907
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07694427)
DESCRIPTION:GSK 5733584\, phase 3\, Ovarian Cancer.\nStudy: Mo-Rez in First
 - Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficien
 t Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]\nEstimated primary comple
 tion: 6 September 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/gsk-5733584#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07694427
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06765109-10952@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:neladalkib: Phase 3 readout est. (NCT06765109)
DESCRIPTION:neladalkib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nela
 dalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC\n
 Estimated primary completion: December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/neladalkib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06765109
URL:https://assetmemo.bio/drug/neladalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802704-2501@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20291205
DTEND;VALUE=DATE:20291206
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07802704)
DESCRIPTION:Risvutatug rezetecan\, phase 3.\nStudy: A Study of Risvutatug R
 ezetecan in Participants With Metastatic Castration-resistant Prostate Can
 cer (mCRPC) [EMBOLD Prostate-302]\nEstimated primary completion: 5 Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-re
 zetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07802704
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07607925-5638@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20300110
DTEND;VALUE=DATE:20300111
SUMMARY:GSK5926371: Phase 1/2 readout est. (NCT07607925)
DESCRIPTION:GSK5926371\, phase 1/2.\nStudy: A Study to Evaluate Safety and 
 Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Ref
 ractory B-NHL\nEstimated primary completion: 10 January 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/gsk5926371#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07607925
URL:https://assetmemo.bio/drug/gsk5926371#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740720-2162@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20300313
DTEND;VALUE=DATE:20300314
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT07740720)
DESCRIPTION:Dostarlimab\, phase 3\, Rectal Cancer.\nStudy: A Study of the D
 uration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Micr
 osatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer\nEstima
 ted primary completion: 13 March 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07740720
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108270-2162@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07108270)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: A Study of 
 Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Particip
 ants With Primary Advanced or Recurrent Endometrial Cancer (EC)\nEstimated
  primary completion: 31 March 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07108270
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684612-9165@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20300521
DTEND;VALUE=DATE:20300522
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07684612)
DESCRIPTION:GSK 5733584\, phase 3\, Ovarian Cancer.\nStudy: A Study to Inve
 stigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doubl
 et With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer
  (BEHOLD-Ovarian02)\nEstimated primary completion: 21 May 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/gsk-5733584#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07684612
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286266-9165@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20300722
DTEND;VALUE=DATE:20300723
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07286266)
DESCRIPTION:GSK 5733584\, phase 3\, Ovarian Cancer.\nStudy: A Study to Inve
 stigate Mocertatug Rezetecan Compared With Standard of Care in Participant
 s With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)\nEstimated pri
 mary completion: 22 July 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/gsk-5733584#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07286266
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227311-3152@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07227311)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: A St
 udy to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combina
 tion With Standard of Care in Participants With Relapsed-Refractory Multip
 le Myeloma (RRMM)\nEstimated primary completion: 30 August 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07227311
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07456033-1527@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20300923
DTEND;VALUE=DATE:20300924
SUMMARY:Depemokimab: Phase 3 readout est. (NCT07456033)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: A Study of Efficacy and
  Safety of Depemokimab Compared With Placebo in Adults and Adolescents Wit
 h at Risk Type 2 Asthma\nEstimated primary completion: 23 September 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/depemokimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07456033
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704892-6690@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20301016
DTEND;VALUE=DATE:20301017
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07704892)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Study to I
 nvestigate Safety and Efficacy of Efimosfermin Compared With Placebo in Ad
 ult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-a
 ssociated Steatohepatitis (MASH)\nEstimated primary completion: 16 October
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/efimosfermin-a
 lfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07704892
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07860450-2162@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20301105
DTEND;VALUE=DATE:20301106
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT07860450)
DESCRIPTION:Dostarlimab\, phase 3\, Endometrial Cancer.\nStudy: Two Part (P
 hase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclita
 xel in Participants With Primary Advanced or Recurrent Endometrial Cancer\
 nEstimated primary completion: 5 November 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07860450
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621601-2501@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07621601)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Esophageal Squamous Cell Carci
 noma.\nStudy: A Study of HS-20093 in Patients With Pretreated Advanced or 
 Metastatic Esophageal Squamous Cell Carcinoma (ESCC)\nEstimated primary co
 mpletion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/risvutatug-rezetecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07621601
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843641-11196@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Velzatinib: Phase 2 readout est. (NCT07843641)
DESCRIPTION:Velzatinib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy: 
 A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
 \nEstimated primary completion: 31 January 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/velzatinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07843641
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679101-3152@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20310428
DTEND;VALUE=DATE:20310429
SUMMARY:Belantamab mafodotin: Phase 3 readout est. (NCT06679101)
DESCRIPTION:Belantamab mafodotin\, phase 3\, Multiple Myeloma.\nStudy: A St
 udy of Belantamab Mafodotin Administered in Combination With Lenalidomide 
 and Dexamethasone (BRd) Versus Daratumumab\, Lenalidomide\, and Dexamethas
 one (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who
  Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)\nEstima
 ted primary completion: 28 April 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06679101
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585266-11196@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20320830
DTEND;VALUE=DATE:20320831
SUMMARY:Velzatinib: Phase 3 readout est. (NCT07585266)
DESCRIPTION:Velzatinib\, phase 3\, Gastrointestinal Stromal Tumor.\nStudy: 
 A Study to Investigate Velzatinib Compared With Imatinib in Adult Particip
 ants With Previously Untreated Metastatic and/or Unresectable Gastrointest
 inal Stromal Tumors (StrateGIST Frontline)\nEstimated primary completion: 
 30 August 2032. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/velza
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07585266
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224672-3152@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20330112
DTEND;VALUE=DATE:20330113
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07224672)
DESCRIPTION:Belantamab mafodotin\, phase 2.\nStudy: A Study to Evaluate the
  Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophos
 phamide\, Bortezomib\, and Dexamethasone in Adult Participants With Newly 
 Diagnosed Amyloid Light Chain (AL) Amyloidosis\nEstimated primary completi
 on: 12 January 2033. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 belantamab-mafodotin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07224672
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701993-6690@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20330623
DTEND;VALUE=DATE:20330624
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07701993)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Pivotal Cl
 inical Study to Investigate the Safety and Efficacy of Efimosfermin Compar
 ed With Placebo in Adult Participants With Compensated Cirrhosis Due to Me
 tabolic Dysfunction-associated Steatohepatitis (MASH)\nEstimated primary c
 ompletion: 23 June 2033. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/efimosfermin-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07701993
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
